Table 4.
Clinicopathological characteristics correlated with categorical low, intermediate and high RKIP expression both in the nucleus and cytoplasm
| Clinico-pathological characteristics | Patients (n=310) | RKIP expression | p value | ||
|---|---|---|---|---|---|
|
| |||||
| Low RKIP nuclear & cytoplasmic expression (n=158) | Intermediate RKIP nuclear & cytoplasmic expression (n=41) | High RKIP nuclear & cytoplasmic expression (n=111) | |||
| Age (≤50/>50 years) | 77/233 | 39/119 | 11/30 | 27/84 | 0.994 |
| Size (≤20/21-50/>50 mm) | 177/122/10 m1 | 81/71/5 m1 | 21/18/2 | 75/33/3 | 0.031 |
| Grade (I/II/III) | 69/130/109 m2 | 24/63/70 m1 | 7/19/15 | 38/48/24 m1 | <0.001 (2.9 × 10-4) |
| Nodal status (negative/positive) | 172/134 m4 | 81/75 m2 | 24/17 | 67/42 m2 | 0.290 |
| Oestrogen receptor status (ER-/ER+) | 89/217 m4 | 61/94 m3 | 6/35 | 22/88 m1 | <0.001 (1.7 × 10-4) |
| Progesterone receptor status (PR-/PR+) | 151/154 m5 | 92/63 m3 | 14/27 | 45/64 m2 | 0.001 |
| HER2 (HER2-/HER2+) | 257/49 m4 | 122/33 m3 | 35/6 | 100/10 m1 | 0.008 |
| Ki67 (≤15/>15) | 224/79 m7 | 104/52 m2 | 28/12 m1 | 92/15 m4 | 0.001 |
| TUNEL (≤0.33/>0.33) | 167/132 m11 | 93/62 m3 | 24/17 | 50/53 m8 | 0.089 |
| Necrosis (absent/present) | 155/147 m8 | 70/83 m5 | 20/21 | 65/43 m3 | 0.067 |
| Chemotherapy (no/yes) | 194/115 m1 | 85/72 m1 | 28/13 | 81/30 | 0.005 |
| Radiotherapy (no/yes) | 176/133 m1 | 94/63 m1 | 27/14 | 55/56 | 0.113 |
| Endocrine therapy (no/yes) | 74/233 m3 | 44/113 m1 | 5/35 m1 | 25/85 m1 | 0.002 |
| DFS (months) | n=152 m6 | n=39 m2 | n=101 m10 | Group 1 vs. Group 2 p=0.023* | |
| Mean (95% CI) | 83.7 (78.6-88.8) | 81.9 (76.2-87.6) | 96.6 (91.6-101.6) | ||
m (number of patients) denotes missing cases.
*
p value for disease free survival pooled over strata (for the whole graph) is 0.072.